Avatrombopag can promote platelet production, but the medication risk is significantly increased in specific populations. The following is an explanation for two key taboos or populations that require high vigilance.

1、 Patients with a history of thromboembolic events

1. Core reasons for risk

This medication may increase the risk of thrombosis. If the patient has previously experienced arterial or venous thrombosis (such as myocardial infarction, stroke, deep vein thrombosis, pulmonary embolism), the use may induce new or recurrent thrombotic events.

2. Principles of medication decision-making

For such patients, doctors need to rigorously evaluate the benefits and risks. Caution should only be considered when there is a high risk of bleeding caused by thrombocytopenia and adequate measures are taken to prevent thrombosis.

3. Key monitoring points during medication use

If the doctor decides to take medication after evaluation, close monitoring of any new thrombotic symptoms such as chest pain, limb swelling, difficulty breathing, or headache should be conducted during the treatment period. If any abnormalities occur, medical attention should be sought immediately.

2、 Severe liver injury patients

1. Classification of liver function and medication restrictions

Avatranib is mainly metabolized by the liver. For patients with Child Pugh classification of C (severe liver dysfunction), drug exposure is significantly increased and the risk of adverse reactions is increased, so it is generally not recommended to use.

2. Moderate liver injury requires dose adjustment

For Child Pugh B (moderate) patients, the starting dose should be adjusted under the guidance of a doctor based on platelet count and liver function indicators, and should not be taken according to the conventional regimen.

3. Liver function monitoring during medication

All patients with liver disease should undergo regular follow-up examinations of transaminase, bilirubin, and coagulation function during medication. If liver function deteriorates or jaundice, ascites, and other symptoms worsen, medication should be discontinued and alternative treatment options evaluated.